Your Messages Inbox
Your Article Summary
See Latest ArticlesShire and Sandoz Settle All Pending Litigation Concerning ADDERALL XR
Shire, 10/14/09
Shire plc, the global specialty biopharmaceutical company, announces that it has settled all pending litigation with Sandoz, Inc. in connection with Sandoz’s Abbreviated New Drug Application and its attempt to market generic versions of Shire’s ADDERALL XR (mixed amphetamine salts) for the treatment of Attention Deficit Hyperactivity Disorder.
Today in Regulatory Issues...keeping you current
Receive free subspecialty "5-minute updates" via email
The Unintended Consequences of Clinical Trials Regulations
PLoS Medicine, 12/04/09
Mandatory Disclosure of Pharmaceutical Industry-Funded Events for Health Professionals
PLoS Medicine, 12/02/09
FDA drug approval intervals from 1997 to 2006: analysis and comparison during information technology implementation
International Journal of Electronic Healthcare , 12/01/09
Article Search
Sponsor